<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68722">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01783340</url>
  </required_header>
  <id_info>
    <org_study_id>MMV</org_study_id>
    <secondary_id>NL42517.000.12</secondary_id>
    <nct_id>NCT01783340</nct_id>
  </id_info>
  <brief_title>Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis</brief_title>
  <acronym>MMV</acronym>
  <official_title>Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the superior protective immunity of the combination of chloroquine
      and azithromycin prophylaxis under Chemoprophylaxis Sporozoites (CPS) immunization versus a
      standard chloroquine prophylactic regimen.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Volunteers falciparum positive by thick smear</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of P. falciparum thick smear negative volunteers on day 21 (protection against challenge infection)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of pre-patent period by thick smear</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of pre-patent period after challenge infection as measured by microscopy (thick smear)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetics of parasitemia by PCR</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Development of parasitemia as measured by PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>One year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Frequency of adverse events in study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune responses</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immune responses between study groups</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Malaria, Falciparum</condition>
  <condition>Chloroquine</condition>
  <condition>Azithromycin</condition>
  <condition>Immunization</condition>
  <arm_group>
    <arm_group_label>Chloroquine and falciparum immunization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive chloroquine prophylaxis, a placebo during immunizations and three times 5 infected mosquito-bites (immunizations). Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.
Placebo capsules daily on three consecutive days starting on each of three immunization days.
Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
When thick smear positive, of at day 21 after challenge, a standard 3 day  treatment of Malarone will be given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chloroquine/Azithromycin  and falciparum immunization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive chloroquine and azithromycin prophylaxis and three times 5 infected mosquito-bites (immunizations).
Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.
Azithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.
Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
When thick smear positive, of at day 21 after challenge, a standard 3 day  treatment of Malarone will be given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chloroquine and Azithromycin control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will receive chloroquine and azithromycin prophylaxis and three times 5 uninfected mosquito-bites during immunization. Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.
Azithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.
Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
When thick smear positive, of at day 21 after challenge, a standard 3 day  treatment of Malarone will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin capsules</intervention_name>
    <arm_group_label>Chloroquine/Azithromycin  and falciparum immunization</arm_group_label>
    <arm_group_label>Chloroquine and Azithromycin control</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Chloroquine and falciparum immunization</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunization with falciparum</intervention_name>
    <arm_group_label>Chloroquine and falciparum immunization</arm_group_label>
    <arm_group_label>Chloroquine/Azithromycin  and falciparum immunization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atovaquone/Proguanil</intervention_name>
    <arm_group_label>Chloroquine and falciparum immunization</arm_group_label>
    <arm_group_label>Chloroquine/Azithromycin  and falciparum immunization</arm_group_label>
    <arm_group_label>Chloroquine and Azithromycin control</arm_group_label>
    <other_name>Malarone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Challenge with falciparum</intervention_name>
    <arm_group_label>Chloroquine and falciparum immunization</arm_group_label>
    <arm_group_label>Chloroquine/Azithromycin  and falciparum immunization</arm_group_label>
    <arm_group_label>Chloroquine and Azithromycin control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 and ≤ 35 years healthy volunteers (males or females)

          2. Good health based on history and clinical examination

          3. Negative pregnancy serum test

          4. For females who are sexually active: use of adequate contraception (incl. condom use)

          5. Signing of the informed consent form, thereby demonstrating understanding of the
             meaning and procedures of the study

          6. Agreement to inform the general practitioner and to sign a request to release medical
             information concerning contra-indications for participation in the study

          7. Willingness to undergo a Pf controlled infection through mosquito bites

          8. Agreement to stay in a hotel room close to the trial centre during a part of the
             study (Day 7 till day 15 after challenge)

          9. Reachable (24/7) by mobile phone during the whole study period

         10. Available to attend all study visits

         11. Agreement to refrain from blood donation to Sanquin or for other purposes, during the
             whole study period

         12. Willingness to undergo HIV, hepatitis B and hepatitis C tests

         13. Negative urine toxicology screening test at screening visit and the day before
             challenge

         14. Willingness to take a prophylactic regime of chloroquine or chloroquine/azithromycin
             combination and a curative regimen of Malarone® after challenge.

        Exclusion Criteria:

          1. History of malaria

          2. Plans to travel to malaria endemic areas during the study period

          3. Plans to travel outside of the Netherlands during the challenge period

          4. History of stay in malaria endemic areas for more than 6 months

          5. Previous participation in any malaria vaccine study and/or positive serology for Pf

          6. Symptoms, physical signs and laboratory values suggestive of systemic disorders
             including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency,
             psychiatric, and other conditions which could interfere with the interpretation of
             the study results or compromise the health of the volunteer

          7. History of diabetes mellitus or cancer (except basal cell carcinoma of the skin)

          8. History of arrhythmias or prolonged QT-interval

          9. Positive family history in 1st and 2nd degree relatives for cardiac events &lt; 50 years
             old

         10. An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by
             the Systematic Coronary Risk Evaluation (SCORE) system

         11. Clinically significant abnormalities in electrocardiogram (ECG) at screening

         12. Body Mass Index (BMI) below 18 or above 30 kg/m2

         13. Any clinically significant deviation from the normal range in biochemistry or
             haematology blood tests or in urine analysis

         14. Positive HIV, HBV or HCV tests

         15. Participation in any other clinical study within 30 days prior to the onset of the
             study

         16. Enrolment in any other clinical study during the study period

         17. Pregnancy or lactation for women

         18. Volunteers unable to give written informed consent

         19. Volunteers unable to be closely followed for social, geographic or psychological
             reasons

         20. History of (soft) drugs or alcohol abuse interfering with normal social function

         21. A history of treatment for psychiatric disease

         22. A history of epileptic insults in the volunteer

         23. Contra-indications for use of Malarone®, chloroquine or azithromycin. This includes
             hypersensitivity or treatment taken by the volunteer that interferes with mentioned
             study drugs.

         24. The use of chronic immunosuppressive drugs, antibiotics, or other immune modifying
             drugs within three months of study onset (topical corticosteroids and oral
             anti-histaminic are allowed) and during the study period

         25. Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             (functional) asplenia

         26. Co-workers or trainees of the departments of Medical Microbiology, Parasitology, or
             Internal Medicine of the Leiden University Medical Centre

         27. A history of sickle cell anaemia, sickle cell trait, thalassemia, thalassemia trait
             or G6PD deficiency
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>RW Sauerwein, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LG Visser, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Remko Schats, MD</last_name>
    <phone>0031715262620</phone>
    <email>r.schats@lumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leo Visser, MD, PhD</last_name>
    <phone>0031715262620</phone>
    <email>l.g.visser@lumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Leiden University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <zip>2333ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Remko Schats, MD</last_name>
      <phone>0031715262620</phone>
      <email>r.schats@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Leo Visser, MD PhD</last_name>
      <phone>0031715262620</phone>
      <email>l.g.visser@lumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Remko Schats, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leo Visser, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maurits van Meer, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, van de Vegte-Bolmer M, van Schaijk B, Teelen K, Arens T, Spaarman L, de Mast Q, Roeffen W, Snounou G, Rénia L, van der Ven A, Hermsen CC, Sauerwein R. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009 Jul 30;361(5):468-77.</citation>
    <PMID>19641203</PMID>
  </results_reference>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>January 31, 2013</lastchanged_date>
  <firstreceived_date>January 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malaria</keyword>
  <keyword>P falciparum</keyword>
  <keyword>Chloroquine</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Immunization</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
    <mesh_term>Proguanil</mesh_term>
    <mesh_term>Atovaquone</mesh_term>
    <mesh_term>Malarone</mesh_term>
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
